OptimizeRx Corporation
OPRXHealthcareNASDAQHealth Information Services · Last scanned Jul 22, 2026
Scan Results
Daily timeframeOptimizeRx Corporation operates as a digital healthcare technology company. With a market capitalization of $125.0M, it sits in micro-cap territory. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail.
Market Cap
$125.0M
Beta
1.08
P/E (TTM)
18.00
P/E (Fwd)
6.12
EPS (TTM)
$0.37
EPS (Fwd)
$1.09
ROE
5.6%
ROA
5.4%
Cash
$20.2M
Total Debt
$23.7M
Free CF
$11.3M
52W Change
-49.9%
Annual Financials
Cash vs Debt
Where OPRX stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, OPRX finished 19.58% below its 150-day moving average ($8.12) and 37.93% below its 200-day moving average ($10.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OPRX overbought or oversold?
At the July 15, 2026 close, OPRX's RSI(14) was 91.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $20.2M in cash, though total debt stands at $23.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $11.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 5.6%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $62.5M (2022) to $109.4M (2025), reflecting a 75% increase over the period.
Investors considering OptimizeRx Corporation should weigh the typical risks associated with OPRX's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for OptimizeRx Corporation and its sector.